Editor’s note: This article and headline was corrected to read iloprost, not albuterol.
A single dose of the drug iloprost (also known as Ventavis) had clinical benefits for COPD patients with pulmonary hypertension, with the greatest benefit for severe COPD-PH patients.
More than half of COPD patients are known to develop PH (COPD-PH). To date, the only treatment shown to slow or reverse disease progression is long-term oxygen therapy.
Results showed that a single dose of inhaled Ventavis led to a substantial improvement in hemodynamic parameters (mean pulmonary artery pressure, pulmonary vascular resistance or PVR, and volume of blood being pumped by the heart), without compromising hypoxic vasoconstriction and gas exchange.